{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:21:19Z","timestamp":1773231679298,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.thromres.2024.109046","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:57:07Z","timestamp":1717574227000},"page":"109046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor\u2013associated major bleeds"],"prefix":"10.1016","volume":"240","author":[{"given":"Raza","family":"Alikhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Nour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ofori-Asenso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stina","family":"Axelsson-Ch\u00e9ramy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Seghal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Yokobori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooks D.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Maegele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2024.109046_bb0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.109046_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2024.109046_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2024.109046_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007338","article-title":"Evidence gaps in the era of non-vitamin K oral anticoagulants","volume":"7","author":"Aronis","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2024.109046_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.1693","article-title":"National trends in use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019","volume":"2","author":"Troy","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.thromres.2024.109046_bb0030","first-page":"S67","article-title":"Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding","volume":"23","author":"Milling","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.thromres.2024.109046_bb0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non-vitamin k antagonist vs vitamin k antagonist oral anticoagulants with in-hospital mortality","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2024.109046_bb0040","article-title":"Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor-associated major bleeding: A real-world analysis of Medicare beneficiaries","volume":"4","author":"Williams","year":"2023","journal-title":"J. Am. Coll. Emerg. Physicians Open"},{"key":"10.1016\/j.thromres.2024.109046_bb0045","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2024.109046_bb0050","series-title":"Lyophilized Powder for Solution for Intravenous Injection [Package Insert]","author":"ANDEXXA\u00ae (coagulation factor Xa (recombinant), inactivated-zhzo)","year":"2018"},{"key":"10.1016\/j.thromres.2024.109046_bb0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annemergmed.2019.09.001","article-title":"Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel","volume":"76","author":"Baugh","year":"2020","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur. Stroke J."},{"key":"10.1016\/j.thromres.2024.109046_bb0070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.109046_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajem.2023.07.042","article-title":"Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding","volume":"73","author":"Brown","year":"2023","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0080","doi-asserted-by":"crossref","first-page":"939","DOI":"10.5811\/WESTJEM.60587","article-title":"Treatment of factor-Xa inhibitor-associated bleeding with Andexanet alfa or 4 factor PCC: a multicenter feasibility retrospective study","volume":"24","author":"Singer","year":"2023","journal-title":"West J. Emerg. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2023.06.021","article-title":"Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors","volume":"229","author":"Pon","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.109046_bb0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11239-022-02752-z","article-title":"Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage","volume":"55","author":"Lipski","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.109046_bb0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11239-022-02715-4","article-title":"Retrospective review of Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of DOAC-associated intracranial hemorrhage","volume":"55","author":"Troyer","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.109046_bb0100","article-title":"Hemostatic efficacy and safety of 4-factor prothrombin complex concentrate in DOAC-associated intracranial hemorrhage","author":"Whaley","year":"2022","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.thromres.2024.109046_bb0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MBC.0000000000001128","article-title":"Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre","volume":"33","author":"Milioglou","year":"2022","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2024.109046_bb0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0115","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s11239-021-02412-8","article-title":"Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral factor Xa inhibitors","volume":"52","author":"Hormese","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.109046_bb0120","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/jcph.1779","article-title":"Outcomes associated with 4-factor prothrombin complex concentrate administration to reverse oral factor Xa inhibitors in bleeding patients","volume":"61","author":"Highsmith","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2024.109046_bb0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12028-020-00968-6","article-title":"Efficacy of 4-factor prothrombin complex concentrates in factor Xa inhibitor-associated intracranial bleeding","volume":"34","author":"Korobey","year":"2021","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.thromres.2024.109046_bb0130","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/jth.15031","article-title":"Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa","volume":"18","author":"Nederpelt","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109046_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106070","article-title":"An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage","volume":"195","author":"Giovino","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.thromres.2024.109046_bb0140","article-title":"Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study","volume":"7","author":"Dobesh","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109046_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","article-title":"Real-world clinical outcomes among US veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate","volume":"56","author":"Sutton","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.109046_bb0150","series-title":"Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Guidance for Industry","author":"Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research","year":"2009"},{"key":"10.1016\/j.thromres.2024.109046_bb0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s41687-020-00219-4","article-title":"The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders","volume":"4","author":"Cruz Rivera","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.thromres.2024.109046_bb0160","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109046_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.thromres.2024.109046_bb0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13104-019-4067-9","article-title":"Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results","volume":"12","author":"Gerlinger","year":"2019","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.thromres.2024.109046_bb0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2217\/cer-2017-0029","article-title":"Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication","volume":"7","author":"Vaidya","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.thromres.2024.109046_bb0180","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0185","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0190","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.10079","article-title":"Availability of specific direct oral anticoagulant reversal agents in US hospitals","volume":"4","author":"Kanjee","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.thromres.2024.109046_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11123399","article-title":"Andexanet alfa for reversal of factor Xa inhibitors in intracranial hemorrhage: observational cohort study","volume":"11","author":"Rauch","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12028-020-01161-5","article-title":"Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage","volume":"35","author":"Ammar","year":"2021","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.thromres.2024.109046_bb0210","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0885066620916706","article-title":"Comparison of low- versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor-associated bleeding: a retrospective study","volume":"36","author":"Wilsey","year":"2021","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11239-020-02154-z","article-title":"Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products","volume":"51","author":"Castillo","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.109046_bb0220","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11239-019-01846-5","article-title":"Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study","volume":"48","author":"Smith","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.109046_bb0225","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11739-018-1977-9","article-title":"Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate","volume":"14","author":"Sheikh-Taha","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0230","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.109046_bb0235","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109046_bb0240","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:02:19Z","timestamp":1720044139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":48,"alternative-id":["S0049384824001786"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109046","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor\u2013associated major bleeds","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109046"}}